


PHARMACEUTICAL 2022



Actinium Pharmaceuticals Inc. Rank 185 of 475





PHARMACEUTICAL 2022



Actinium Pharmaceuticals Inc. Rank 185 of 475

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 204% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -45%, being 231% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	79,749
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,840
Liabilities, Non-Current	0
Other Assets	299
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3.0
Other Net Income	190
Property and Equipment	340
Research and Development	18,031
Revenues	1,144
Selling, General and Administrative Expense	8,077

Output Variable	Value in 1000 USD
Assets	80,388
Liabilities	6,843
Expenses	26,108
Stockholders Equity	73,545
Net Income	-24,774
Comprehensive Net Income	-24,774
Economic Capital Ratio	-45%